UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the month of April 2017
Commission File Number: 001-37569
STRONGBRIDGE BIOPHARMA plc
(Exact name of Registrant as specified in its charter)
900 Northbrook Drive
Suite 200
Trevose, PA 19053
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
The information contained in the exhibits to this Form 6-K is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Strongbridge Biopharma’s registration statements or other filings with the Commission.
Exhibits
Exhibit |
| Exhibit Table |
|
|
|
99.1 |
| Notice of Annual General Meeting of Strongbridge Biopharma plc to be held on 11 May 2017 |
|
|
|
99.2 |
| Directors Report and Consolidated Financial Statements for the Financial Year Ended December 31, 2016 |
|
|
|
99.3 |
| Form of Proxy Card |